Bristol Myers Squibb (CELG-RI) EBIT Margin (2009 - 2026)
Bristol Myers Squibb's (CELG-RI) quarterly EBIT Margin came in at 2.77% in Q2 2026, up 1581.0% year-over-year from 0.17% in Q2 2025, and up 275.18% quarter-over-quarter from 1.58% in Q1 2026.
Powered by 
Analysis
Bristol Myers Squibb (CELG-RI) EBIT Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported EBIT Margin for 18 consecutive years, with 2.77% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBIT Margin rose 1581.0% year-over-year to 2.77% in Q2 2026; TTM through Jun 2026 was 5.63%, a 1026.0% increase from a year earlier, with the FY2025 full-year figure at 9.56%, up 3671.0% from the prior year.
- EBIT Margin was 2.77% for Q2 2026 at Bristol Myers Squibb, up from 1.58% in the prior quarter.
- Over five years, EBIT Margin peaked at 2.77% in Q2 2026 and troughed at 121.77% in Q1 2024.
- A 5-year average of 14.62% and a median of 6.58% in 2022 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin tumbled 12357 bps in 2024 and jumped 12122 bps in 2025, its largest moves.
- Over 5 years, EBIT Margin stood at 6.44% in 2022, then sank by 45 bps to 9.33% in 2023, then slumped by 303 bps to 37.57% in 2024, then jumped by 44 bps to 21.01% in 2025, then soared by 113 bps to 2.77% in 2026.
- The last three EBIT Margin figures came in at 2.77% (Q2 2026), 1.58% (Q1 2026), and 21.01% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 42.23% |
| 10 | Bristol Myers Squibb | 285.98 Mn | -10.78 Bn | 9.25 Bn | 2.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.77% |
| Mar 31, 2026 | -1.58% |
| Dec 31, 2025 | -21.01% |
| Sep 30, 2025 | -2.63% |
| Jun 30, 2025 | -13.03% |
| Mar 31, 2025 | -0.55% |
| Dec 31, 2024 | -37.57% |
| Sep 30, 2024 | -10.77% |
| Jun 30, 2024 | -16.24% |
| Mar 31, 2024 | -121.77% |
| Dec 31, 2023 | -9.33% |
| Sep 30, 2023 | -3.36% |
| Jun 30, 2023 | -9.06% |
| Mar 31, 2023 | 1.80% |
| Dec 31, 2022 | -6.44% |
| Sep 30, 2022 | -1.28% |
| Jun 30, 2022 | -6.41% |
| Mar 31, 2022 | -6.73% |
| Dec 31, 2021 | -4.16% |
| Sep 30, 2021 | -1.15% |